Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and
biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without
weekly docetaxel in subjects with advanced solid tumors.